Developments in CD4 and viral load monitoring in resource-limited settings

Clinical Infectious Diseases

Volumn 58, Issue 3, 2014, Pages 407-412

  Rowley, Christopher F ^a,b,c,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^d Division of Infectious Diseases Laboratory   (United States)

Author keywords

CD4; HIV; resource limited; treatment monitoring; viral load

Indexed keywords

CD4 ANTIGEN;

ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DRIED BLOOD SPOT TESTING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LABORATORY DEVICE; LABORATORY TEST; MONITORING; NONHUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; VIRUS EXAMINATION; VIRUS LOAD;

CD4; HIV; RESOURCE-LIMITED; TREATMENT MONITORING; VIRAL LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DRUG MONITORING; HIV; HIV INFECTIONS; HUMANS; POINT-OF-CARE SYSTEMS; VIRAL LOAD;

EID: 84892733448     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit733     Document Type: Article

References (50)

1. Arnedo M, Alonso E, Eisenberg N, et al. Monitoring HIV viral load in resource limited settings: still a matter of debate? PLoS One 2012; 7: e47391.
2. Ford N, Roberts T, Calmy A. Viral load monitoring in resource-limited settings: a medical and public health priority. AIDS 2012; 26:1719-20.
3. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treatment and Preventing HIV Infection. Geneva, Switzerland: WHO, 2013.
4. Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011; 343: d6792.
5. Kahn JG, Marseille E, Moore D, et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ 2011; 343:d6884.
6. Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 2011; 53: 1283-90.
7. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antire-troviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49:454-62.
8. Westley BP, DeLong AK, Tray CS, et al. Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children. Clin Infect Dis 2012; 55:432-40.
9. Group A-LoISKeiser O, Tweya H, Boulle A, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23:1867-74.
10. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
11. Medina Lara A, Kigozi J, Amurwon J, et al. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretrovi-ral therapy in Uganda and Zimbabwe. PloS One 2012; 7:e33672.
12. Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54:258-68.
13. Braithwaite RS, Nucifora KA, Yiannoutsos CT, et al. Alternative antire-troviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J Int AIDS Soc 2011; 14:38.
14. Walensky RP, Ciaranello AL, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis 2010; 51:85-92
15. UNITAID. HIV/AIDS diagnostic technology landscape. 2nd ed. 2012. Available at: http://www.unitaid.eu/images/marketdynamics/publications/UNITAID- HIV-Diagnostics-Landscape-2nd-edition.pdf. Accessed 7 November 2013.
16. Thairu L, Katzenstein D, Israelski D. Operational challenges in delivering CD4 diagnostics in sub-Saharan Africa. AIDS Care 2011; 23:814-21.
17. World Health Organization. The treatment 2.0 framework for action: catalysing the next phase of treatment, care and support. 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241501934- eng.pdf. Accessed 7 November 2013.
18. Mandala J, Torpey K, Kasonde P, et al. Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers. BMC Public Health 2009; 9:314.
19. Bergeron M, Daneau G, Ding T, et al. Performance of the PointCare NOW system for CD4 counting in HIV patients based on five independent evaluations. PloS One 2012; 7:e41166.
20. Sukapirom K, Onlamoon N, Thepthai C, Polsrila K, Tassaneetrithep B, Pattanapanyasat K. Performance evaluation of the Alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings. J Acquir Immune Defic Syndr 2011; 58:141-7.
21. Herbert S, Edwards S, Carrick G, et al. Evaluation of PIMA point-of-care CD4 testing in a large UK HIV service. Sex Transm Infect 2012; 88:413-7.
22. Mnyani CN, McIntyre JA, Myer L. The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antire-troviral therapy. J Acquir Immune Defic Syndr 2012; 60:260-4.
23. Manabe YC, Wang Y, Elbireer A, Auerbach B, Castelnuovo B. Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy. PloS One 2012; 7: e34319.
24. Glencross DK, Coetzee LM, Faal M, et al. Performance evaluation of the Pima point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa. J Int AIDS Soc 2012; 15:3.
25. Larson B, Schnippel K, Ndibongo B, Long L, Fox MP, Rosen S. How to estimate the cost of point-of-care CD4 testing in program settings: an example using the Alere Pima Analyzer in South Africa. PLoS One 2012; 7:e35444.
26. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 2011; 378:1572-9.
27. Logan C, Givens M, Ives JT, et al. Performance evaluation of the MBio Diagnostics point-of-care CD4 counter. J Immunol Methods 2013; 387:107-13.
28. UNITAID. HIV/AIDS Diagnostics Technology Landscape, Semiannual Update 2012. Available at: http://www.unitaid.eu/images/marketdynamics/publications/ UNITAID-2012-Semi-annual-Update- HIV-Diagnostics-Technology-Landscape.pdf.pdf. Accessed 7 November 2013.
29. Stevens WS, Marshall TM. Challenges in implementing HIV load testing in South Africa. J Infect Dis 2010; 201 (Suppl 1):S78-84.
30. Greig J, du Cros P, Klarkowski D, et al. Viral load testing in a resource-limited setting: quality control is critical. J Int AIDS Soc 2011; 14:23.
31. Lee HH, Dineva MA, Chua YL, Ritchie AV, Ushiro-Lumb I, Wisniewski CA. Simple amplification-based assay: a nucleic acid-based point-of-care platform for HIV-1 testing. J Infect Dis 2010; 201 (Suppl 1): S65-72.
32. Tanriverdi S, Chen L, Chen S. A rapid and automated sample-to-result HIV load test for near-patient application. J Infect Dis 2010; 201 (Suppl 1):S52-8.
33. Okonji JA, Basavaraju SV, Mwangi J, et al. Comparison of HIV-1 detection in plasma specimens and dried blood spots using the Roche COBAS Ampliscreen HIV-1 test in Kisumu, Kenya. J Virol Methods 2012; 179:21-5.
34. Viljoen J, Gampini S, Danaviah S, et al. Dried blood spot HIV-1 RNA quantification using open real-time systems in South Africa and Burkina Faso. J Acquir Immune Defic Syndr 2010; 55:290-8.
35. Johannessen A, Garrido C, Zahonero N, Naman E, de Mendoza C. HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System. J Antimicrob Chemother 2011; 66:260-4.
36. Rottinghaus EK, Ugbena R, Diallo K, et al. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretro-viral therapy. Clin Infect Dis 2012; 54:1187-95.
37. Vidya M, Saravanan S, Rifkin S, et al. Dried blood spots versus plasma for the quantitation of HIV-1 RNA using a real-time PCR, m2000rt assay. J Virol Methods 2012; 181:177-81.
38. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005; 352:1873-83.
39. Sullivan TJ, Patel P, Hutchinson A, Ethridge SF, Parker MM. Evaluation of pooling strategies for acute HIV-1 infection screening using nucleic acid amplification testing. J Clin Microbiol 2011; 49:3667-8.
40. van Zyl GU, Preiser W, Potschka S, Lundershausen AT, Haubrich R, Smith D. Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting. Clin Infect Dis 2011; 52:264-70.
41. Tilghman MW, Guerena DD, Licea A, et al. Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico. J Acquir Immune Defic Syndr 2011; 56:e70-4.
42. May S, Gamst A, Haubrich R, Benson C, Smith DM. Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr 2010; 53:194-201.
43. Smith DM, May SJ, Perez-Santiago J, et al. The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS 2009; 23:2151-8.
44. Creek TL, Alwano MG, Molosiwa RR, et al. Botswana's Tebelopele voluntary HIV counseling and testing network: use and client risk factors for HIV infection, 2000-2004. J Acquir Immune Defic Syndr 2006; 43:210-8.
45. Marum E, Taegtmeyer M, Parekh B, et al. "What took you so long?" The impact of PEPFAR on the expansion of HIV testing and counseling services in Africa. J Acquir Immune Defic Syndr 2012; 60 (Suppl 3): S63-9.
46. Heller T, Kunthea S, Bunthoeun E, et al. Point-of-care HIV testing at antenatal care and maternity sites: experience in Battambang Province, Cambodia. Int J STD AIDS 2011; 22:742-7.
47. Larson BA, Schnippel K, Ndibongo B, et al. Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa. J Acquir Immune Defic Syndr 2012; 61:e13-7.
48. Estill J, Egger M, Blaser N, et al. Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study. AIDS 2013; 27:1483-92.
49. Kahn JG, Marseille EA. Viral load monitoring for antiretroviral therapy in resource-poor settings: an evolving role. AIDS 2013; 27: 1509-11.
50. Medecins sans Frontieres. UNITAID greenlights proposal to implement POC CD4 tests and routine viral monitoring. May 10, 2012. Available at: http://www.msf-me.org/en/news/news-media/news-press-releases/ unitaid-greenlights-proposal-to-implement-poc-cd4-tests-and-routine-viral- monitoring-1.html. Accessed 7 November 2013.